Your Source for Venture Capital and Private Equity Financings

Vizgen Announces $37M Series B Financing

2021-04-07
CAMBRIDGE, MA, Vizgen, the life science company dedicated to advancing human health by visualizing single-cell spatial genomics information, has closed a $37 million Series B financing.
The financing was co-led by Novalis LifeSciences LLC, and current investor Northpond Ventures. Also participating in the round were new investors Tao Capital Partners, Pura Vida Investments, LLC, and a large U.S. endowment fund. Current investors joining the round included ARCH Venture Partners and David Walt, Ph.D., Professor at Harvard Medical School, Core Faculty at the Wyss Institute, and co-founder of Vizgen.

Vizgen is developing the next generation of genomic profiling tools that enable researchers to gain new insight into the biological systems that underlie human health and disease with spatial context. The company's MERSCOPETM platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors